Response to "Clinically Significant Rhinosinusitis Can Be Asymptomatic".

Clinically Significant Rhinosinusitis Can Be Asymptomatic.

The effect of nasally administered budesonide respules on adrenal cortex function in patients with chronic rhinosinusitis.

OBJECTIVES To evaluate whether nasal administration of budesonide in adults with chronic rhinosinusitis for 30 days suppresses adrenal function and to assess its clinical efficacy. DESIGN An open-label prospective study. SETTING Academic medical center. PATIENTS We assessed adrenal function in 9 patients using the cosyntropin test before and after budesonide therapy. INTERVENTION Budeso...

Emerging Role of Proteases in the Pathogenesis of Chronic Rhinosinusitis with Nasal Polyps

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous upper airway disease with multiple etiologies. Clinically, CRSwNP can be classified into either eosinophilic or non-eosinophilic subtypes. The eosinophilic phenotype of CRSwNP is widely thought to be highly associated with recurrence of nasal polyps or surgical failure. Epithelial cells have a crucial role in the development o...

Intravenous tranexamic acid and intraoperative visualization during functional endoscopic sinus surgery: a double-blind randomized controlled trial.

BACKGROUND Bleeding during endoscopic sinus surgery (ESS) can hinder surgical progress and may be associated with increased complications. Tranexamic acid is an antifibrinolytic that is known to reduce operative bleeding. The current study was designed to assess the effect of adjunctive intravenous tranexamic acid on intraoperative bleeding and the quality of the surgical field during ESS. ME...

Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis.

OBJECTIVE A herbal drug combination (Dry Extract BNO 1016) has been assessed for efficacy and tolerability in patients with acute viral rhinosinusitis. METHODOLOGY In this randomised, controlled trial patients with symptom duration of up to 3 days, mild to moderate facial pain and a Major Symptom Score (MSS) between 8 and 12 were treated for 15 days with BNO 1016 or placebo (coated tablets ad...